Phase II study of hypofractionated proton beam therapy for localized prostate cancer

Phase II study of hypofractionated proton beam therapy for localized prostate cancer - hypofractionated proton therapy for prostate cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017679

Enrollment

120

Registered

2015-06-01

Start date

2015-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Hypofractionation

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: T1c-T3aN0M0 Prostate cancer

Exclusion criteria

Exclusion criteria: Severe complications such as heart failure, and liver dysfunction other active malignant tumors history of pelvis irradiation not to allow discontinuing anticoagulant and antiplatelet therapy severe cognitive impairment

Design outcomes

Primary

Measure	Time frame
5-year grade 2 late toxicity rate	—

Secondary

Measure	Time frame
Acute reaction, late tpxicity, 5 year survival, 5 year progression free survival	—

Countries

Japan

Contacts

Public ContactHitoshi Ishikawa

University of Tsukuba, Faculty of Medicine Radiation Oncology

hishikawa@pmrc.tsukuba.ac.jp029-853-7100

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026